Market Overview

UPDATE: Benchmark Raises PT on Cardiovascular Systems on Fiscal 2014 Estimates

Related CSII
Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks
How To Profit From An Aging Population

In a report published Friday, Benchmark Company analyst James Terwilliger reiterated his Speculative Buy rating on Cardiovascular Systems (NASDAQ: CSII), and raised his price target from $18.00 to $24.00.

In the report, Terwilliger noted, “We are publishing our fiscal 2014 revenue and EPS estimates of $125 million and ($0.78). This represents 25% revenue growth compared to our fiscal 2013 revenue estimate of $100 million. Our fiscal 2014 EPS estimate of ($0.78) compares favorably to our fiscal 2013 EPS estimate of ($1.09). The main driver of the improvement in our bottom line results is our assumption that CSII receives regulatory approval for their cardiology application with a subsequent launch in Q1:14 of calendar 2014.”

Cardiovascular Systems closed on Thursday at $20.30.

Latest Ratings for CSII

May 2014Bank of AmericaInitiates Coverage onBuy
Mar 2014NeedhamInitiates Coverage onStrong Buy
Feb 2014WunderlichTerminatesBuy

View More Analyst Ratings for CSII
View the Latest Analyst Ratings

Posted-In: Benchmark CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (CSII)

View Comments and Join the Discussion!

Get Benzinga's Newsletters